FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022087185> ?p ?o ?g. }

• W2022087185 endingPage "473" @default.
• W2022087185 startingPage "473" @default.
• W2022087185 abstract "The concentration of natural killer (NK) cells is lower in HIV-infected patients than in HIV-seronegative individuals, and a low concentration of NK cells in the blood has been associated with rapid disease progression [1]. In addition, increased plasma HIV-1 RNA level is related to low levels of NK cytotoxicity and low NK cell activity, both of which are associated with a high risk of progression to a CD4 T lymphocyte count of less than 100 × 106 and to death in HIV-infected patients [2]. However, the effect of HAART on NK cells is not fully defined. We studied the number of CD16 NK cells in a series of 66 consecutive HIV-infected patients (age 38 ± 8 years; 55 men, 11 women), in whom the viral load remained below 200 copies/ml after treatment with highly active antiretroviral therapy (HAART) (lamivudine plus stavudine plus saquinavir in 15 patients, lamivudine plus stavudine plus indinavir in 25 patients, 11 other HAART combinations in the other 26 patients). As a control group, we evaluated 10 patients, matched for age and sex, with the same risk practices but showing an unsatisfactory response to HAART. Lymphocyte subsets were determined by flow cytometry (Orthocytoron, Raritan, NJ, USA) using TRIO reagents (OKT4A-FITC/OKT8-PE/OKT3CyP and NK-FITC/OKT319APE/OKT3CyP). Plasma HIV-1 RNA was measured using the Amplicor HIV-1 monitor (Roche, Branchburg, NJ, USA), with 200 copies/ml as the lower limit of detection. Lymphocyte subsets and HIV-1 RNA were monitored at the outset and at 4, 12, 24, 36 and 48 weeks after treatment. The basal conditions (mean ± SD) were: CD4 cells: 215 ± 64.5 cells/μl (range 4–729); CD8 cells: 796 ± 573.6 cells/μl (range 81–3023); CD19 B cells: 102 ± 97.02 cells/μl (range 8–606); CD16 NK cells: 60.45 ± 43.05 (range 7–205); and viral load (log10 RNA copies/ml): 4.48 ± 1.17 (range 2.0–6.6). For statistical analysis, Wilcoxon, Spearman's and Kruskal–Wallis tests were performed. Our results (Fig. 1) did not show a statistical increase in CD16 NK cells at 4 weeks after HAART. However, peripheral blood CD16 NK cells increased at 12 weeks of HAART in HIV-1-infected patients in whom the viral load after treatment was below 200 copies/ml. This increase was maintained at 24, 36 and 48 weeks. Taking into account the whole treatment period, a positive correlation between both CD4 lymphocytes and NK cell levels was found in the HIV-1-treated patients. The NK cell number was not significantly different in the control group of HIV-1 individuals, whose viral load did not descend below detectable levels (data not shown).Fig. 1.: Levels of CD4 cells, CD8 cells, CD16 natural killer cells and HIV-1 viral load in patients who have received highly active antiretroviral therapy over 12 months.Previously, changes in NK levels were not observed in patients with HAART [3]. However, the follow-up of the patients in our study was 12 months and was restricted to those patients with a viral load that remained under detectable levels, whereas the NK cell number analysis in Lederman et al. [3] was at 12 weeks and only 17 out of 40 patients achieved HIV-1 RNA levels below 100 copies/ml. Very little is known about the survival, proliferation kinetics and distribution of NK cells after HAART. It could be postulated that the NK cell reconstitution after HAART presented here is directly related to the decreased virus burden and subsequent cessation of NK cell destruction, or to NK cell expansion secondary to an amelioration of the T cell compartment. In this respect, it is likely that normalized levels of cytokines after CD4 T cell reconstitution support NK cell differentiation. However, the possibility of a peripheral expansion of the pre-existing mature NK cell pool, as was suggested for T cells, cannot be excluded. This hypothesis is supported by the observation reported in this study, that the CD4 T cell increase precedes the CD16 NK increase by 2 months. It is also possible that an effective control of virus replication by potent drug combinations offers hope of effective therapeutic assistance to non-major histocompatibility complex restricted cytotoxicity in controlling HIV infection. Further studies will be necessary to elucidate these questions and clarify the effect of HAART on NK functional capacity. José Luis Villanuevaa Javier Caballeroa Marta Del Nozala Berta Sanchezb Pompeyo Vicianaa Arístides Alarcóna José Peñac" @default.
• W2022087185 created "2016-06-24" @default.
• W2022087185 creator A5027308727 @default.
• W2022087185 creator A5032090907 @default.
• W2022087185 creator A5039448683 @default.
• W2022087185 creator A5060151497 @default.
• W2022087185 creator A5070851237 @default.
• W2022087185 creator A5078883792 @default.
• W2022087185 creator A5080754332 @default.
• W2022087185 date "2000-03-01" @default.
• W2022087185 modified "2023-10-16" @default.
• W2022087185 title "Peripheral blood natural killer cell reconstitution after highly active antiretroviral therapy" @default.
• W2022087185 cites W2064558165 @default.
• W2022087185 cites W2077050911 @default.
• W2022087185 cites W2121956497 @default.
• W2022087185 doi "https://doi.org/10.1097/00002030-200003100-00030" @default.
• W2022087185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10770559" @default.
• W2022087185 hasPublicationYear "2000" @default.
• W2022087185 type Work @default.
• W2022087185 sameAs 2022087185 @default.
• W2022087185 citedByCount "7" @default.
• W2022087185 crossrefType "journal-article" @default.
• W2022087185 hasAuthorship W2022087185A5027308727 @default.
• W2022087185 hasAuthorship W2022087185A5032090907 @default.
• W2022087185 hasAuthorship W2022087185A5039448683 @default.
• W2022087185 hasAuthorship W2022087185A5060151497 @default.
• W2022087185 hasAuthorship W2022087185A5070851237 @default.
• W2022087185 hasAuthorship W2022087185A5078883792 @default.
• W2022087185 hasAuthorship W2022087185A5080754332 @default.
• W2022087185 hasBestOaLocation W20220871851 @default.
• W2022087185 hasConcept C10205521 @default.
• W2022087185 hasConcept C109316439 @default.
• W2022087185 hasConcept C114684123 @default.
• W2022087185 hasConcept C126322002 @default.
• W2022087185 hasConcept C142462285 @default.
• W2022087185 hasConcept C159047783 @default.
• W2022087185 hasConcept C159912055 @default.
• W2022087185 hasConcept C167672396 @default.
• W2022087185 hasConcept C202751555 @default.
• W2022087185 hasConcept C203014093 @default.
• W2022087185 hasConcept C2522874641 @default.
• W2022087185 hasConcept C2776937687 @default.
• W2022087185 hasConcept C2777210460 @default.
• W2022087185 hasConcept C2777761686 @default.
• W2022087185 hasConcept C2777869810 @default.
• W2022087185 hasConcept C2778102761 @default.
• W2022087185 hasConcept C2779690655 @default.
• W2022087185 hasConcept C2779889181 @default.
• W2022087185 hasConcept C2780593183 @default.
• W2022087185 hasConcept C2780727368 @default.
• W2022087185 hasConcept C2781462264 @default.
• W2022087185 hasConcept C28328180 @default.
• W2022087185 hasConcept C2993143319 @default.
• W2022087185 hasConcept C54355233 @default.
• W2022087185 hasConcept C55493867 @default.
• W2022087185 hasConcept C71924100 @default.
• W2022087185 hasConcept C86803240 @default.
• W2022087185 hasConcept C8891405 @default.
• W2022087185 hasConcept C90924648 @default.
• W2022087185 hasConceptScore W2022087185C10205521 @default.
• W2022087185 hasConceptScore W2022087185C109316439 @default.
• W2022087185 hasConceptScore W2022087185C114684123 @default.
• W2022087185 hasConceptScore W2022087185C126322002 @default.
• W2022087185 hasConceptScore W2022087185C142462285 @default.
• W2022087185 hasConceptScore W2022087185C159047783 @default.
• W2022087185 hasConceptScore W2022087185C159912055 @default.
• W2022087185 hasConceptScore W2022087185C167672396 @default.
• W2022087185 hasConceptScore W2022087185C202751555 @default.
• W2022087185 hasConceptScore W2022087185C203014093 @default.
• W2022087185 hasConceptScore W2022087185C2522874641 @default.
• W2022087185 hasConceptScore W2022087185C2776937687 @default.
• W2022087185 hasConceptScore W2022087185C2777210460 @default.
• W2022087185 hasConceptScore W2022087185C2777761686 @default.
• W2022087185 hasConceptScore W2022087185C2777869810 @default.
• W2022087185 hasConceptScore W2022087185C2778102761 @default.
• W2022087185 hasConceptScore W2022087185C2779690655 @default.
• W2022087185 hasConceptScore W2022087185C2779889181 @default.
• W2022087185 hasConceptScore W2022087185C2780593183 @default.
• W2022087185 hasConceptScore W2022087185C2780727368 @default.
• W2022087185 hasConceptScore W2022087185C2781462264 @default.
• W2022087185 hasConceptScore W2022087185C28328180 @default.
• W2022087185 hasConceptScore W2022087185C2993143319 @default.
• W2022087185 hasConceptScore W2022087185C54355233 @default.
• W2022087185 hasConceptScore W2022087185C55493867 @default.
• W2022087185 hasConceptScore W2022087185C71924100 @default.
• W2022087185 hasConceptScore W2022087185C86803240 @default.
• W2022087185 hasConceptScore W2022087185C8891405 @default.
• W2022087185 hasConceptScore W2022087185C90924648 @default.
• W2022087185 hasIssue "4" @default.
• W2022087185 hasLocation W20220871851 @default.
• W2022087185 hasLocation W20220871852 @default.
• W2022087185 hasOpenAccess W2022087185 @default.
• W2022087185 hasPrimaryLocation W20220871851 @default.
• W2022087185 hasRelatedWork W2039429451 @default.
• W2022087185 hasRelatedWork W2066184048 @default.
• W2022087185 hasRelatedWork W2070504323 @default.
• W2022087185 hasRelatedWork W2125787947 @default.
• W2022087185 hasRelatedWork W2163500912 @default.

• next